Vytalyou, a Mumbai-based preventive health and longevity startup, has raised ₹9 crore in a pre-Series A funding round, valuing the young company at about ₹33 crore. The round, announced on 30 September 2026, was backed by two industry investors: Chetan Jain of pharmaceutical distributor Pharma Dose and Ratan Jain of Venus Industries.
The company will use the funds to expand its network of what it calls Incremental Lifestyle Clinics, starting in Mumbai, where it currently operates a single facility in Powai. It plans to open two more centres in the city by the end of the year and eventually reach ten locations across India.
Founded by specialist doctors
Vytalyou was founded in 2025 by Dr Chirantan Bose, a molecular oncologist, and Dr Preetesh Bhandari, a radiologist. Their backgrounds shape the company's model. Both specialties deal with diseases that are often detected late, when treatment is harder and more expensive, and both rely heavily on diagnostic data.
The company combines diagnostic testing with personalised treatment plans delivered under medical supervision. Its predictive longevity evaluations draw on a wide range of tests, including pathology, radiology, cardiac and respiratory assessments, body composition analysis, genetic testing, cancer screening and gut microbiome evaluation. It also offers personalised intravenous therapies as part of some programmes.
Vytalyou says it has served about 1,000 clients so far.
Why preventive care is gaining ground
India faces a rapidly growing burden of lifestyle-related, non-communicable diseases such as diabetes, heart disease, hypertension and certain cancers. According to World Health Organization estimates, these conditions now account for the majority of deaths in the country. Many are linked to diet, physical inactivity, stress, pollution and tobacco use, and many can be delayed or prevented with early detection and lifestyle changes.
Yet India's healthcare system remains largely reactive. Most people visit a doctor only when they are sick, and routine health check-ups often consist of standardised test packages with little follow-up. Vytalyou is betting that a growing number of urban, affluent and health-conscious Indians will pay for a more continuous, doctor-led approach that uses detailed data to guide long-term lifestyle changes.
The global longevity boom
The startup is part of a much wider global movement. Longevity clinics, which promise to help people extend not only lifespan but healthy lifespan, have attracted significant investment in the United States, Europe and the Middle East. Wealthy clients pay for detailed scans, biomarker tracking and personalised programmes designed to reduce their risk of chronic disease.
On the same day Vytalyou announced its funding, Amsterdam-based Blue Health Intelligence raised €3.4 million for its preventive health assessment clinics, which offer a one-hour evaluation for €299 and are fully booked through November. The parallel shows how preventive health has become an investable category across very different markets.
In India, the opportunity is shaped by local economics. Diagnostic tests are generally much cheaper than in Western countries, which makes comprehensive screening more affordable. At the same time, consumers are price-sensitive, and many are sceptical of paying for care when they feel healthy.
Scrutiny of the science
The longevity industry also faces legitimate questions. Medical experts caution that some tests and therapies marketed for longevity, including certain genetic tests, microbiome analyses and intravenous infusions, have limited evidence for improving health outcomes in people without symptoms. Over-testing can also lead to false alarms, anxiety and unnecessary follow-up procedures.
Vytalyou's emphasis on doctor supervision, rather than direct-to-consumer testing without medical interpretation, is intended to address some of those concerns. Having specialists review results and design programmes can help ensure that testing is used to guide sensible clinical decisions rather than simply to generate data. How the company balances evidence-based prevention with premium wellness services will be important for its credibility as it grows.
A capital-light expansion plan
Vytalyou's expansion plan is relatively modest compared with venture-backed healthcare chains, and the ₹9 crore round reflects that. The money will be used for clinic expansion, medical equipment, hiring specialists, technology development, patient acquisition and building operational infrastructure.
Opening clinics in Mumbai first allows the company to refine its model in a single market with high concentrations of affluent consumers before moving to other cities. Mumbai, Delhi NCR, Bengaluru and Hyderabad are the most likely next markets for a premium preventive health service.
The economics of a clinic-led model differ sharply from those of a pure diagnostics company. A diagnostic lab earns money per test and scales by collecting samples from as many people as possible. A longevity clinic aims to build ongoing relationships with fewer clients, earning revenue from repeated assessments, programmes and follow-up care. That means higher revenue per client but also higher costs, since specialist doctors, equipment and premium locations are expensive. The ₹33 crore valuation implies that investors see early promise in client retention, although the company has not disclosed revenue figures.
Corporate wellness could become an important channel. Many Indian employers already pay for annual health check-ups for staff, and some are beginning to offer more comprehensive preventive programmes for senior employees. A doctor-led longevity offering could fit naturally into such benefit packages, giving the company a route to scale beyond individual walk-in customers.
Industry investors bring distribution knowledge
The investors' backgrounds are notable. Chetan Jain's Pharma Dose operates in pharmaceutical distribution, while Ratan Jain is associated with Venus Industries. Strategic investors from adjacent industries can offer supply chain relationships, procurement expertise and business networks that help a young healthcare company manage costs and scale operations.
The road ahead
Vytalyou enters a market with several types of competitors: large diagnostic chains that offer health check-up packages, hospital-based preventive health programmes, wellness startups and international longevity brands that are beginning to target India's wealthiest consumers. To stand out, the company will need to show that its programmes produce measurable health improvements for clients and that it can deliver a consistent experience across multiple locations.
If it succeeds, Vytalyou could help establish a new category in Indian healthcare: preventive care that is personal, data-driven and continuous rather than a once-a-year blood test. With lifestyle diseases rising and a growing middle class willing to invest in its health, the timing for such a model may be right. The next phase will reveal whether demand extends beyond early adopters in Mumbai to a broader national market.
